Market Research Logo

Postherpetic Neuralgia - Pipeline Review, H2 2015

Postherpetic Neuralgia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Postherpetic Neuralgia - Pipeline Review, H2 2015’, provides an overview of the Postherpetic Neuralgia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Postherpetic Neuralgia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Postherpetic Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Postherpetic Neuralgia Overview
Therapeutics Development
Pipeline Products for Postherpetic Neuralgia - Overview
Pipeline Products for Postherpetic Neuralgia - Comparative Analysis
Postherpetic Neuralgia - Therapeutics under Development by Companies
Postherpetic Neuralgia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Postherpetic Neuralgia - Products under Development by Companies
Postherpetic Neuralgia - Companies Involved in Therapeutics Development
Aestus Therapeutics, Inc.
Allergan Plc
Astellas Pharma Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Immune Pharmaceuticals Inc.
Merck & Co., Inc.
Nuvo Research Inc.
Pfizer Inc.
Phosphagenics Limited
Purdue Pharma L.P.
Relmada Therapeutics, Inc.
Scilex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Winston Pharmaceuticals, Inc.
Postherpetic Neuralgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(naltrexone hydrochloride+ clonidine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-8477 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATX-08001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-746 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNV-2197944 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWP-05195 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flexicaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
funapide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine hydrochloride patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mepivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8291 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NXN-462 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxycodone ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
senrebotase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-116517 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Postherpetic Neuralgia - Recent Pipeline Updates
Postherpetic Neuralgia - Dormant Projects
Postherpetic Neuralgia - Discontinued Products
Postherpetic Neuralgia - Product Development Milestones
Featured News & Press Releases
Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia
Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100
Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido
Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Postherpetic Neuralgia, H2 2015
Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Allergan Plc, H2 2015
Postherpetic Neuralgia - Pipeline by Astellas Pharma Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Nuvo Research Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H2 2015
Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H2 2015
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2015
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Postherpetic Neuralgia - Pipeline by Winston Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H2 2015
Postherpetic Neuralgia - Dormant Projects, H2 2015
Postherpetic Neuralgia - Dormant Projects (Contd..1), H2 2015
Postherpetic Neuralgia - Dormant Projects (Contd..2), H2 2015
Postherpetic Neuralgia - Discontinued Products, H2 2015
Postherpetic Neuralgia - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Postherpetic Neuralgia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report